ClinicalTrials.gg
CompletedNCT05479812Updated Nov 10, 2026

Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of WTX-124 and pembrolizumab in Metastatic Solid Tumor and Advanced Solid Tumor, sponsored by Werewolf Therapeutics, Inc.. Completed at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Werewolf Therapeutics, Inc. · Phase 1, Interventional, and Treatment

How we know · 10 judgments

Updated Oct 9, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
156
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,057 studies in Neoplasm Metastasis with a site in United States — 344 open to participants now, 544 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Enrollment
372nd of 1,866
156 · median 43
Started
2022
with 105 others
Phase 1
710 of 2,057
127 open now
Registered
1,697th of 2,057
by date

Among the 2,057 studies in Neoplasm Metastasis with a site in United States, this one is the 372nd largest by enrollment of the 1,866 interventional ones that give a count, is one of 106 that started in 2022, is one of 710 in phase 1, and was the 1,697th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

344 of the 2,057 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

339 more — sign in →

All 344 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,057 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

A first-in-human, Phase I, open-label, multicenter study of WTX-124 administered as monotherapy and in combination with pembrolizumab to patients with advanced or metastatic solid tumors.

Read the detailed description

This is a first-in-human, Phase I, open-label, multicenter study designed to evaluate the safety, tolerability and preliminary efficacy of WTX-124, a conditionally-activated IL-2 prodrug, when administered as monotherapy and in combination with pembrolizumab, for the treatment of patients with advanced solid tumors. Part 1 of the study is dose escalation of WTX-124, both as monotherapy and in combination with pembrolizumab. Part 2 is dose expansion and is comprised of six arms in which WTX-124 will be administered as monotherapy and in combination with pembrolizumab to patients with advanced or metastatic cutaneous malignant melanoma or advanced or metastatic renal cell carcinoma.

03

Conditions studied

  • Metastatic Solid Tumor
  • Advanced Solid Tumor

Keywords

  • WTX-124
  • pembrolizumab
  • Tumors
  • Cutaneous Malignant Melanoma
  • mRCC
  • Renal Carcinoma
  • IL-2
  • Cutaneous SCC (cutaneous squamous cell carcinoma)
  • NSCLC (non-small cell lung cancer)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Each patient must meet all the following criteria to participate in the study:

  1. Has histological or cytological documentation of a solid tumor indication for which a CPI (e.g. anti-PD-(L)1 is indicated for all parts of the clinical study;
  2. Monotherapy Dose Escalation:

    Patients with locally advanced or solid tumors for which immunotherapy is approved, who have progressed on or are intolerant to standard therapy, including CPIs, or for whom no standard therapy with proven benefit exists.

    Combination Dose Escalation:

    Patients with relapsed/refractory locally advanced or metastatic solid tumors for which immunotherapy is approved, who have progressed on or are intolerant to standard therapy or for whom no standard therapy with proven benefit exists.

    Monotherapy Dose Expansion:

    • Arm A: Patients with relapsed advanced or metastatic RCC who have received no more than 4 in the advanced or metastatic setting
    • Arm B: Patients with relapsed advanced or metastatic cutaneous malignant melanoma who have received no more than 2 prior lines of therapy for BRAF V600 wild type and no more than 3 prior lines of therapy for BRAF V600 mutant melanoma.
    • Arm C: Patients with relapsed advanced or metastatic cSCC who have received no more than 2 prior lines of systemic therapy

    Combination Dose Expansion:

    1. Arm D: Patients with RCC who have received no more than 3 prior lines of therapy
    2. Arm E: Patients with cutaneous melanoma who may be naïve to all prior therapy for advanced or metastatic disease. For BRAF wild type melanoma, patients should have received no more than 2 prior lines of therapy. For BRAF V600 mutant disease, patients should have received no more than 3 prior lines of therapy.
    3. Arm F: Patients with -positive NSCLC who have received no more than 3 prior lines;
  3. ≥18 years of age;
  4. (ECOG) Performance Status of 0 or 1;
  5. Has at least 1 per 1.1(lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions);
  6. Agrees to undergo a pre-treatment and on-treatment of a primary or metastatic solid tumor lesion;
  7. Has adequate organ and bone marrow function;
  8. Willingness of men and women of to observe highly effective for the duration of treatment and for 4 months following the last dose of study drug;
  9. Additional criteria may apply

Exclusion criteria

Exclusion Criteria:

  1. Have a history of another active (a second cancer) within the previous 2 years except for localized cancers that are not related to the current cancer being treated, are considered cured, and, in the opinion of the Investigator, presents a low risk of recurrence. These exceptions include, but are not limited to, basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast;
  2. Has a history of (non-infectious) pneumonitis / interstitial lung disease that required or has current pneumonitis / interstitial lung disease;
  3. Have received prior IL-2-directed therapy;
  4. Have had an allogeneic tissue/solid organ transplant;
  5. Have known symptomatic requiring steroids;
  6. Have significant cardiovascular disease;
  7. Have an active disease that required systemic treatment in the past 2 years;
  8. Diagnosis of immunodeficiency, is on therapy, or is receiving chronic systemic or enteric steroid therapy
  9. Major surgery (excluding placement of vascular access) within 2 weeks prior to the first dose of study drug;
  10. agent or anticancer therapy within 5 half-lives or 4 weeks (whichever is shorter) prior to the first dose of study drug;
  11. Has received prior radiotherapy within 2 weeks of start of study treatment. A 1-week is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease;
  12. Any unresolved toxicities from prior therapy greater than version 5.0 Grade 1 at the time of starting study drug with the exception of alopecia and Grade 2 prior platinum-therapy related neuropathy;
  13. Received a live or within 30 days of the first dose of study drug; Note: Administration of killed vaccines or other formats are allowed.
  14. Active, uncontrolled systemic bacterial, viral, or fungal infection;
  15. -infected participants with a history of Kaposi sarcoma and/or Multicentric Castleman Disease;
  16. Active infection as determined by surface antigen and hepatitis B core antibody, or hepatitis B virus DNA by quantitative polymerase chain reaction (qPCR) testing;
  17. Active infection as determined by virus (HCV) antibody or HCV RNA by qPCR testing;
  18. Pregnant or lactating;
  19. History of to any of the study drug components;
  20. Additional criteria may apply.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
156 participants (actual)

Study arms

  • Experimental
    WTX-124 monotherapy dose escalation

    WTX-124 monotherapy dose escalation

    Drug: WTX-124

  • Experimental
    WTX-124 in combination with pembro dose escalation

    WTX-124 in combination with pembrolizumab (pembro) dose escalation

    Drug: WTX-124 · Drug: pembrolizumab

  • Experimental
    Arm A: WTX-124 monotherapy dose expansion. Patients with advanced or metastatic RCC.

    Arm A: WTX-124 monotherapy dose expansion. Patients with advanced or metastatic RCC.

    Drug: WTX-124

  • Experimental
    Arm B: WTX-124 monotherapy dose expansion. Advanced or metastatic cutaneous malignant melanoma.

    Arm B: WTX-124 monotherapy dose expansion. Patients with advanced or metastatic cutaneous malignant melanoma.

    Drug: WTX-124

  • Experimental
    Arm C: WTX-124 monotherapy dose expansion. Patients with advanced or metastatic cSCC.

    Arm C: WTX-124 monotherapy dose expansion. Patients with advanced or metastatic cSCC.

    Drug: WTX-124

  • Experimental
    Arm D: WTX-124 in combination with pembro dose expansion. Advanced or metastatic RCC.

    Arm D: WTX-124 in combination with pembrolizumab dose expansion. Patients with advanced or metastatic RCC.

    Drug: WTX-124 · Drug: pembrolizumab

  • Experimental
    Arm E: WTX-124 with pembro dose expansion. Advanced or metastatic cutaneous melanoma.

    Arm E: WTX-124 in combination with pembrolizumab dose expansion. Patients with advanced or metastatic cutaneous melanoma.

    Drug: WTX-124 · Drug: pembrolizumab

  • Experimental
    Arm F: WTX-124 in combination with pembro dose expansion. Advanced/metastatic PD-L1-positive NSCL

    Arm F: WTX-124 in combination with pembrolizumab dose expansion. Patients with advanced or metastatic PD-L1-positive NSCLC lines.

    Drug: WTX-124 · Drug: pembrolizumab

Interventions

  • DrugWTX-124

    Investigation Product Monotherapy

  • Investigation Product in combination with approved therapy

    Also known as: KEYTRUDA®

06

What researchers measure

Primary outcomes

  1. Incidence of Dose Limiting Toxicities (DLTs) in monotherapy and combination therapy

    Time frame: 4 weeks

  2. Incidence of treatment emergent adverse events in monotherapy and combination therapy

    Time frame: 24 months

  3. Incidence of changes in clinical laboratory abnormalities in monotherapy and combination therapy

    Time frame: 24 months

  4. Dose Expansion - Incidence of Dose Limiting Toxicities (DLTs) in monotherapy and combination therapy

    Time frame: 4 weeks

  5. Dose Expansion - Incidence of treatment emergent adverse events in monotherapy and combination therapy

    Time frame: 24 months

  6. Dose Expansion - Incidence of changes in clinical laboratory abnormalities in monotherapy and combination therapy

    Time frame: 24 months

  7. Dose Expansion - Investigator-assessed objective response rate (ORR) per RECIST 1.1 and iORR by iRECIST in monotherapy and combination therapy

    Time frame: 24 months

Secondary outcomes

  1. Plasma concentrations of WTX-124 and free IL-2

    Time frame: 24 months

  2. Investigator-assessed objective response rate (ORR) per RECIST 1.1 and iORR by iRECIST in monotherapy and combination therapy

    Time frame: 24 months

  3. Changes in circulating immune cell populations in response to monotherapy and combination therapy

    Time frame: 24 months

  4. Changes in soluble cytokines in response to monotherapy and combination therapy

    Time frame: 24 months

  5. Changes in tumor immune profile in response to monotherapy and combination therapy

    Time frame: 24 months

  6. Investigator-assessed objective response rate (ORR) per RECIST 1.1 and iORR by iRECIST in monotherapy and combination therapy (in advanced or metastatic renal cell carcinoma and advanced or metastatic cutaneous malignant melanoma)

    Time frame: 24 months

  7. Antidrug antibody (ADA) occurrence

    Time frame: 24 months

  8. Duration of response

    Time frame: 24 months

  9. Progression free survival

    Time frame: 24 months

  10. Overall survival

    Time frame: 36 months

  11. To investigate immunological biomarkers in peripheral blood and tumor that may correlate with the treatment outcome of WTX-124 as monotherapy or in combination with pembrolizumab

    Time frame: 24 months

  12. To assess tumor biopsies for potential biomarkers of target engagement and immune pathway activation

    Time frame: 24 months

07

Study locations

14 sites
  • HonorHealth
    Scottsdale, Arizona 85258, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Emory Winship Cancer Institute
    Atlanta, Georgia 30322, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center
    Indianapolis, Indiana 46202, United States
  • Minnesota Oncology Hematology, P.A.
    Maple Grove, Minnesota 55369, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Roswell Park Comprehensive Cancer Care
    Buffalo, New York 14203, United States
  • Westchester Medical Center
    Hawthorne, New York 10532, United States
  • Providence Cancer Institute Franz Clinic
    Portland, Oregon 97213, United States
  • Texas Oncology - Austin Midtown
    Austin, Texas 78705-1165, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390-8852, United States
  • NEXT Oncology
    Houston, Texas 77054, United States
  • NEXT Oncology
    San Antonio, Texas 78229, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Apr 2026, 44 months.

Of 289 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's 44 months is close to that.

Counting every sponsor, half of 498 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

Start moved once since we started tracking on Sep 25, 2026: May 2022 → Aug 2022, on Oct 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2022
First posted
Jul 29, 2022
StartActual
Aug 15, 2022was May 2022
Primary completionActual
Apr 22, 2026
CompletionActual
Apr 22, 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
May 20, 2022→Aug 15, 2022
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Start date May 20, 2022→Aug 15, 2022

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05479812
Lead sponsor
Werewolf Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jul 29, 2022
Start date
Aug 15, 2022
Primary completion
Apr 22, 2026
Completion
Apr 22, 2026
Last update
Nov 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion